Search research articles
Contact Us
Filters
Showing results (81-90 of 97) with videos related to
Page
of 10
Sort By:
Ugeskrift for Laeger
|
April 16, 2013
[Changes in thyroid disease in Denmark]
Peter Laurberg, Stine Linding Andersen, Anne Krejbjerg Motavaf, et al.
The Journal of Clinical Endocrinology and Metabolism
|
December 15, 2018
Increased Incidence Rate of Hypothyroidism After Iodine Fortification in Denmark: A 20-Year Prospective Population-Based Study
Mads Petersen, Nils Knudsen, Allan Carlé, et al.
Clinical Endocrinology
|
June 1, 2018
Thyrotoxicosis after iodine fortification. A 21-year Danish population-based study
Mads Petersen, Nils Knudsen, Allan Carlé, et al.
The Journal of Clinical Endocrinology and Metabolism
|
September 11, 2012
Predictors of change in serum TSH after iodine fortification: an 11-year follow-up to the DanThyr study
Lena Bjergved, Torben Jørgensen, Hans Perrild, et al.
Ugeskrift for Laeger
|
December 14, 2011
[Iodine fortification of salt and thyroid disease in Denmark]
Peter Laurberg, Torben Jørgensen, Lars Ovesen, et al.
BMC Endocrine Disorders
|
June 26, 2012
A prospective randomised cross-over study of the effect of insulin analogues and human insulin on the frequency of severe hypoglycaemia in patients with type 1 diabetes and recurrent hypoglycaemia (the HypoAna trial): study rationale and design
Peter Lommer Kristensen, Ulrik Pedersen-Bjergaard, Henning Beck-Nielsen, et al.
Diabetes Technology & Therapeutics
|
March 23, 2018
Effect of Insulin Analogs on Frequency of Non-Severe Hypoglycemia in Patients with Type 1 Diabetes Prone to Severe Hypoglycemia: Much Higher Rates Detected by Continuous Glucose Monitoring than by Self-Monitoring of Blood Glucose-The HypoAna Trial
Rikke Mette Agesen, Peter Lommer Kristensen, Henning Beck-Nielsen, et al.
Diabetes Research and Clinical Practice
|
December 25, 2016
The potential for improvement of outcomes by personalized insulin treatment of type 1 diabetes as assessed by analysis of single-patient data from a randomized controlled cross-over insulin trial
Ulrik Pedersen-Bjergaard, Peter L Kristensen, Henning Beck-Nielsen, et al.
Diabetes/Metabolism Research and Reviews
|
February 18, 2011
Efficacy and safety of the PPARγ partial agonist balaglitazone compared with pioglitazone and placebo: a phase III, randomized, parallel-group study in patients with type 2 diabetes on stable insulin therapy
Kim Henriksen, Inger Byrjalsen, Per Qvist, et al.
The Lancet. Diabetes & Endocrinology
|
May 6, 2014
Effect of insulin analogues on risk of severe hypoglycaemia in patients with type 1 diabetes prone to recurrent severe hypoglycaemia (HypoAna trial): a prospective, randomised, open-label, blinded-endpoint crossover trial
Ulrik Pedersen-Bjergaard, Peter Lommer Kristensen, Henning Beck-Nielsen, et al.
Page
of 10
Search research articles
Search
Showing results (81-90 of 97) with videos related to
Sort By:
Page
of 10
Ugeskrift for Laeger
|
April 16, 2013
[Changes in thyroid disease in Denmark]
Peter Laurberg, Stine Linding Andersen, Anne Krejbjerg Motavaf, et al.
The Journal of Clinical Endocrinology and Metabolism
|
December 15, 2018
Increased Incidence Rate of Hypothyroidism After Iodine Fortification in Denmark: A 20-Year Prospective Population-Based Study
Mads Petersen, Nils Knudsen, Allan Carlé, et al.
Clinical Endocrinology
|
June 1, 2018
Thyrotoxicosis after iodine fortification. A 21-year Danish population-based study
Mads Petersen, Nils Knudsen, Allan Carlé, et al.
The Journal of Clinical Endocrinology and Metabolism
|
September 11, 2012
Predictors of change in serum TSH after iodine fortification: an 11-year follow-up to the DanThyr study
Lena Bjergved, Torben Jørgensen, Hans Perrild, et al.
Ugeskrift for Laeger
|
December 14, 2011
[Iodine fortification of salt and thyroid disease in Denmark]
Peter Laurberg, Torben Jørgensen, Lars Ovesen, et al.
BMC Endocrine Disorders
|
June 26, 2012
A prospective randomised cross-over study of the effect of insulin analogues and human insulin on the frequency of severe hypoglycaemia in patients with type 1 diabetes and recurrent hypoglycaemia (the HypoAna trial): study rationale and design
Peter Lommer Kristensen, Ulrik Pedersen-Bjergaard, Henning Beck-Nielsen, et al.
Diabetes Technology & Therapeutics
|
March 23, 2018
Effect of Insulin Analogs on Frequency of Non-Severe Hypoglycemia in Patients with Type 1 Diabetes Prone to Severe Hypoglycemia: Much Higher Rates Detected by Continuous Glucose Monitoring than by Self-Monitoring of Blood Glucose-The HypoAna Trial
Rikke Mette Agesen, Peter Lommer Kristensen, Henning Beck-Nielsen, et al.
Diabetes Research and Clinical Practice
|
December 25, 2016
The potential for improvement of outcomes by personalized insulin treatment of type 1 diabetes as assessed by analysis of single-patient data from a randomized controlled cross-over insulin trial
Ulrik Pedersen-Bjergaard, Peter L Kristensen, Henning Beck-Nielsen, et al.
Diabetes/Metabolism Research and Reviews
|
February 18, 2011
Efficacy and safety of the PPARγ partial agonist balaglitazone compared with pioglitazone and placebo: a phase III, randomized, parallel-group study in patients with type 2 diabetes on stable insulin therapy
Kim Henriksen, Inger Byrjalsen, Per Qvist, et al.
The Lancet. Diabetes & Endocrinology
|
May 6, 2014
Effect of insulin analogues on risk of severe hypoglycaemia in patients with type 1 diabetes prone to recurrent severe hypoglycaemia (HypoAna trial): a prospective, randomised, open-label, blinded-endpoint crossover trial
Ulrik Pedersen-Bjergaard, Peter Lommer Kristensen, Henning Beck-Nielsen, et al.
Page
of 10